Ann: RAP Licenses Additional Pneumonia Diagnostic from UniQuest, page-157

If that is achieved the minimum shareprice will be around $1.60 IMO. That would be assuming a net revenue of $40m and PE of 30.

Normally such a PE would be for stocks that have consistent earnings but no potential growth in sight. Given (all things going well)that the next 6 months - 1 year will only uncover the tip of the iceberg, I think this will run into the 100+ PE shareprice on the foretaste of earnings.

Right now the market is waiting for evidence of a strong commercial pathway. the market doesn't like silence, and tires of the same hope and hype being rehashed. But an absence of news from management doesn't mean that nothing is happening in the background. The FDA pathway is the most important concern for management right now.

However I'd be thinking that establishing deals with Telehealth partners embedded with the clause 'subject to FDA approval' wouldn't be such a silly idea at this point in time .

Cheers
CT